Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced three poster presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists. The presentations focus on:
1. Efficacy and safety of sotagliflozin in patients with Type 1 Diabetes and Chronic Kidney Disease
2. Impact of sotagliflozin as an add-on to basal insulin-treated Type 2 Diabetes
3. Patient-reported burden of disease in Diabetic Peripheral Neuropathic Pain
Dr. Craig Granowitz, Lexicon's CMO, highlighted the importance of the data on sotagliflozin's clinical effect in people with T1D and CKD, noting their high risk of kidney failure and cardiovascular events due to poor glycemic control.
Lexicon Pharmaceuticals (Nasdaq: LXRX) ha annunciato tre presentazioni poster durante la Conferenza Annuale 2024 dell'Associazione dei Professionisti della Cura e dell'Educazione del Diabete. Le presentazioni si concentrano su:
1. Efficacia e sicurezza di sotagliflozin nei pazienti con Diabete di Tipo 1 e Malattia Renale Cronica
2. Impatto di sotagliflozin come aggiunta ai pazienti con Diabete di Tipo 2 trattati con insulina basale
3. Carico della malattia riportato dai pazienti in caso di Dolore Neuropatico Periferico Diabetico
Il Dr. Craig Granowitz, CMO di Lexicon, ha evidenziato l'importanza dei dati sull'effetto clinico di sotagliflozin in persone affette da T1D e CKD, sottolineando il loro alto rischio di insufficienza renale ed eventi cardiovascolari a causa del cattivo controllo glicemico.
Lexicon Pharmaceuticals (Nasdaq: LXRX) anunció tres presentaciones de póster en la Conferencia Anual 2024 de la Asociación de Especialistas en Cuidado y Educación de la Diabetes. Las presentaciones se centran en:
1. Eficacia y seguridad de sotagliflozina en pacientes con Diabetes Tipo 1 y Enfermedad Renal Crónica
2. Impacto de sotagliflozina como complemento en pacientes con Diabetes Tipo 2 que reciben tratamiento con insulina basal
3. Carga de enfermedad reportada por los pacientes en Dolor Neuropático Periférico Diabético
El Dr. Craig Granowitz, CMO de Lexicon, destacó la importancia de los datos sobre el efecto clínico de sotagliflozina en personas con T1D y CKD, señalando su alto riesgo de insuficiencia renal y eventos cardiovasculares debido al mal control glucémico.
Lexicon Pharmaceuticals (Nasdaq: LXRX)는 2024년 당뇨병 관리 및 교육 전문 협회의 연례 회의에서 세 가지 포스터 발표를 했습니다. 발표 내용은 다음과 같습니다:
1. 제1형 당뇨병과 만성 신장병 환자에서의 소타글리플로진의 효능 및 안전성
2. 기저 인슐린 치료를 받는 제2형 당뇨병 환자에서 소타글리플로진의 추가 효과
3. 당뇨병성 말초 신경병증 통증에 대한 환자가 보고한 질병 부담
Lexicon의 CMO인 Craig Granowitz 박사는 T1D와 CKD 환자에서 소타글리플로진의 임상적 효과에 대한 데이터의 중요성을 강조하며, 이들이 혈당 조절 불량으로 인해 신부전 및 심혈관 사건의 높은 위험에 처해 있다고 언급했습니다.
Lexicon Pharmaceuticals (Nasdaq: LXRX) a annoncé trois présentations de posters lors de la Conférence Annuelle 2024 de l'Association des Spécialistes des Soins et de l'Éducation Diabétiques. Les présentations portent sur :
1. Efficacité et sécurité de sotagliflozine chez les patients atteints de Diabète de Type 1 et de Maladie Rénale Chronique
2. Impact de sotagliflozine en ajout à l'insuline basale pour les patients atteints de Diabète de Type 2
3. Charge de la maladie rapportée par les patients concernant la Pain Neuropathique Diabétique
Dr. Craig Granowitz, CMO de Lexicon, a souligné l'importance des données concernant l'effet clinique de sotagliflozine chez les personnes atteintes de T1D et de CKD, notant leur risque élevé d'insuffisance rénale et d'événements cardiovasculaires en raison d'un mauvais contrôle glycémique.
Lexicon Pharmaceuticals (Nasdaq: LXRX) hat drei Posterpräsentationen auf der 2024 Jahreskonferenz der Association of Diabetes Care & Education Specialists angekündigt. Die Präsentationen konzentrieren sich auf:
1. Wirksamkeit und Sicherheit von Sotagliflozin bei Patienten mit Typ-1-Diabetes und chronischer Nierenerkrankung
2. Einfluss von Sotagliflozin als Ergänzung zur basal insulinbehandelten Typ-2-Diabetes
3. Vom Patienten berichtete Krankheitslast bei diabetischer peripherer Neuropathie
Dr. Craig Granowitz, CMO von Lexicon, hob die Bedeutung der Daten zur klinischen Wirkung von Sotagliflozin bei Menschen mit T1D und CKD hervor und wies auf ihr hohes Risiko für Nierenversagen und kardiale Ereignisse aufgrund einer schlechten glykämischen Kontrolle hin.
- Lexicon Pharmaceuticals is presenting data on sotagliflozin's efficacy and safety in multiple diabetes-related conditions
- The company is addressing high-risk patient groups with Type 1 Diabetes and Chronic Kidney Disease
- Lexicon is exploring sotagliflozin as an add-on therapy for inadequately controlled Type 2 Diabetes
- None.
THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Posters will be displayed in the poster area of Exhibition Hall B from Friday, August 9 through Sunday, August 12. All three presentations will occur on Saturday, August 10, 12:15 - 1:15 p.m. CT. Details are as follows:
- “Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease,” Poster #P103, presented by Michael J. Davies, Ph.D., Executive Director, Clinical Development, Lexicon Pharmaceuticals, Inc.
- “Impact of Sotagliflozin, a Dual Sodium–Glucose Cotransporter 1/2 Inhibitor, as Add-on to Inadequately Controlled Basal Insulin–Treated Type 2 Diabetes,” Poster #P104, presented by Amy K. Carroll, Ph.D., Vice President, Medical Affairs, Lexicon Pharmaceuticals, Inc.
- “Patient-Reported Burden of Disease in Diabetic Peripheral Neuropathic Pain—Learnings from In-depth Patient Interviews—Substudy of RELIEF-DPN 1,” Poster #P105, presented by M. Belinda Hardin, PharmD, BCPS, Director, Medical Communications, Lexicon Pharmaceuticals, Inc.
“It’s well-established that people with type 1 diabetes (T1D) and chronic kidney disease (CKD) are at high risk of progression to kidney failure and cardiovascular events due to poor glycemic control,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer. “We look forward to engaging with diabetes educators at the ADCES conference about this important data on the clinical effect of sotagliflozin as an adjunct to insulin in people with T1D and CKD.”
About Sotagliflozin
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients.
About LX9211
Discovered using Lexicon’s unique approach to gene science, LX9211 is a potent, orally delivered, selective, investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1). Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain and identified LX9211 and another development candidate in a neuroscience drug discovery alliance with Bristol-Myers Squibb from which Lexicon holds exclusive development and commercialization rights. Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways. LX9211 has received Fast Track designation from the U.S. Food and Drug Administration for development in diabetic peripheral neuropathic pain.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has commercially launched one of these medicines, INPEFA® (sotagliflozin) in the United States, and has a pipeline of other promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
What are the key topics of Lexicon Pharmaceuticals' (LXRX) presentations at the 2024 ADCES conference?
When and where will Lexicon Pharmaceuticals (LXRX) present its research at the 2024 ADCES conference?
What is the significance of Lexicon Pharmaceuticals' (LXRX) research on sotagliflozin for Type 1 Diabetes patients with Chronic Kidney Disease?
